Tag #Pain Relief

Showing 1 to 4 of 4 results

dailymail.co.uk

🌐 85% Global Worthiness

Aug 1, 01:13

Gene Therapy Shows Promise for Long-Term Osteoarthritis Pain Relief

A Phase 1 clinical trial at the Mayo Clinic successfully tested a gene therapy for osteoarthritis in nine patients, showing reduced pain and improved knee mobility for at least a year after a single injection of a genetically-modified virus delivering an anti-inflammatory molecule, with only minor s...

Gene Therapy Shows Promise for Long-Term Osteoarthritis Pain Relief

A Phase 1 clinical trial at the Mayo Clinic successfully tested a gene therapy for osteoarthritis in nine patients, showing reduced pain and improved knee mobility for at least a year after a single injection of a genetically-modified virus delivering an anti-inflammatory molecule, with only minor s...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate implications of the successful Phase 1 trial of the novel gene therapy for osteoarthritis?

A novel gene therapy for osteoarthritis, currently in Phase 1 trials, shows promise in reducing pain and improving knee mobility in patients for at least a year with a single injection. Nine participants experienced pain reduction and increased mobility after receiving three injections of a genetically-modified virus delivering an anti-inflammatory molecule. No serious side effects were reported.

cnn.com

🌐 85% Global Worthiness

Jan 31, 04:09

FDA Approves First New Painkiller in Over Two Decades

The FDA approved Journavx (suztrigine), a new non-opioid pain reliever, offering a safer alternative to opioids; clinical trials showed effectiveness in reducing post-surgical pain, though further research on chronic pain is needed.

FDA Approves First New Painkiller in Over Two Decades

The FDA approved Journavx (suztrigine), a new non-opioid pain reliever, offering a safer alternative to opioids; clinical trials showed effectiveness in reducing post-surgical pain, though further research on chronic pain is needed.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does Journavx's mechanism of action differ from opioids, and what are the implications for addiction and pain relief?

Journavx's mechanism differs from opioids by blocking pain signals before they reach the brain, preventing addiction potential. Clinical trials demonstrated pain reduction comparable to Vicodin for post-surgical pain, although its efficacy for chronic pain like sciatica requires further investigation. The drug's development was inspired by a unique Pakistani family immune to pain.

theguardian.com

🌐 85% Global Worthiness

Mar 28, 22:10

Antibiotic Drug Shows Promise for Chronic Back Pain

A new antibiotic drug, PP353, shows promise in treating chronic lower back pain caused by infection, with early trials indicating that 60% of 44 participants experienced significant pain and disability reduction; however, further trials are needed before widespread availability.

Antibiotic Drug Shows Promise for Chronic Back Pain

A new antibiotic drug, PP353, shows promise in treating chronic lower back pain caused by infection, with early trials indicating that 60% of 44 participants experienced significant pain and disability reduction; however, further trials are needed before widespread availability.

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the successful trial of PP353 on chronic lower back pain treatment?

A new antibiotic drug, PP353, shows promise in treating chronic lower back pain caused by infection. Early trials indicate 60% of participants experienced significant pain and disability reduction. Further trials are needed before widespread availability.

edition.cnn.com

🌐 85% Global Worthiness

Jan 31, 07:09

FDA Approves First New Pain Reliever in Over Two Decades

The FDA approved Journavx (suztrigine), a new non-opioid pain reliever, offering a safer alternative to opioids; clinical trials showed effectiveness in reducing post-surgical pain, but further research is needed for chronic pain.

FDA Approves First New Pain Reliever in Over Two Decades

The FDA approved Journavx (suztrigine), a new non-opioid pain reliever, offering a safer alternative to opioids; clinical trials showed effectiveness in reducing post-surgical pain, but further research is needed for chronic pain.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of the FDA's approval of Journavx, and how does it address the current healthcare landscape?

The FDA approved Journavx (suztrigine), a new non-opioid pain reliever, offering an alternative to opioids. This 50mg pill, taken every 12 hours after a larger initial dose, showed effectiveness in reducing pain after surgeries in clinical trials. About half of the 80 million Americans who receive prescriptions for moderate to severe pain annually receive opioid-based medications, highlighting the need for safer alternatives.

Showing 1 to 4 of 4 results